Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Treatments after Prostate Surgery

22.01.2009
Although primary prostate surgery or radiotherapy is successful in many cases of prostate cancer, some patients will suffer a recurrence of the disease, which is most often first detected by a measurable PSA blood test.

This so-called biochemical recurrence affects 30% to 40% of patients after surgery. One risk factor for recurrence, the presence of cancer potentially outside the prostate after surgery, will affect about a third of men. Two studies in the March 2009 issue of The Journal of Urology report on clinical studies of treatment options.

Men who show increasing Prostate-Specific-Antigen (PSA) after surgery but without signs of metastases are offered a variety of options for treatment, including radiation, prostatectomy, observation or androgen deprivation therapy (ADT). Unfortunately virtually all patients treated with ADT progress to metastatic disease. Researchers investigated the addition of thalidomide to intermittent ADT in a double-blind, placebo-controlled multicenter study.

Intermittent ADT is increasingly being used in patients with biochemical recurrence since it has some advantages over continuous ADT. In this study, patients were first given ADT for 6 months, followed by thalidomide or placebo until their PSA increased (Oral Phase A) and the authors found that the median time to PSA increase was 15 months for the thalidomide patients versus 9.6 months for placebo. The next phase, Oral Phase B (OPB), was another 6 months of ADT followed by thalidomide and placebo, now switched between patient groups. During OPB, the median time to PSA increase was 17.1 months for thalidomide and 6.6 months for placebo.

Research conducted in 1994 found that thalidomide, an agent originally synthesized in 1954 and used as a sedative until it was linked to more than 10,000 severe malformations in infants, had antiangiogenic activity.

Writing in the article, William D. Figg, Medical Oncology Branch of the National Cancer Institute, National Institutes of Health, states, “Thalidomide is associated with an increase in PSA progression-free survival in men with biochemically recurrent prostate cancer after intermittent ADT. These effects were independent of any effects on testosterone. This is the first study to our knowledge to demonstrate the effects of thalidomide using intermittent hormonal therapy.”

Another multi-institution study, led by Ian M. Thompson, MD, University of Texas Health Science Center at San Antonio, demonstrates that adjuvant radiotherapy significantly improves survival after radical prostatectomy in patients with advanced prostate cancer. In this study initiated in 1988 of 425 men with aggressive prostate cancer, 211 were observed after surgery for signs of recurrence, and 214 received adjuvant radiotherapy shortly after surgery. Unlike most studies which have based results on PSA recurrence, this study’s endpoint was development of metastatic disease.

When data were most recently evaluated in 2008 after an average 12.7 year follow-up, radiation was found to significantly reduce the risk of metastases by 29% and significantly improved survival by 28%. In addition to the most important outcomes of prostate cancer (metastases and survival), the risk of a detectable PSA after surgery (the first evidence of disease recurrence) was reduced by 58% and delayed by more than 7 years. The authors found that all risk groups studied appeared to benefit.

Radiation therapy also significantly reduced the need for hormone therapy after surgery, a treatment which can have profound negative impacts on quality of life. Using measures of quality of life, the study found increases in patients’ urinary and bowel symptoms in the radiotherapy group at six weeks and two years, but these differences subsequently disappeared.

Dr. Thompson commented that “Adjuvant radiotherapy within 18 weeks after radical prostatectomy in a man with pT3N0M0 prostate cancer significantly reduces the risk of PSA recurrence, metastasis and the need for hormonal therapy, and significantly increases survival. All of the approximate 30,000 men each year that face this condition should be informed of the results of this study.”

Featured articles are “A Double Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo in Patients With Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation” by William D. Figg, Maha H.Hussain, James L. Gulley, Philip M. Arlen, Jeanny B. Aragon-Ching, Daniel P. Petrylak, Celestina S. Higano, Seth M. Steinberg, Gurkamal S. Chatta, Howard Parnes, John J. Wright, Oliver Sartor and William L. Dahut, and “Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial” by Ian M. Thompson, Catherine M. Tangen, Jorge Paradelo, M. Scott Lucia, Gary Miller, Dean Troyer, Edward Messing, Jeffrey Forman, Joseph Chin, Gregory Swanson, Edith Canby-Hagino and E. David Crawford.

Both appear in The Journal of Urology, Volume 181, Issue 3 (March 2009) published by Elsevier.

Linda Gruner | alfa
Further information:
http://www.elsevier.com

More articles from Health and Medicine:

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

NASA examines newly formed Tropical Depression 3W in 3-D

26.04.2017 | Earth Sciences

New High-Performance Center Translational Medical Engineering

26.04.2017 | Health and Medicine

NASA's Fermi catches gamma-ray flashes from tropical storms

25.04.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>